MAP3K8 and prostate carcinoma: Next, to determine whether ADI prostate cancer cells are dependent on TPL2 for their ADI cell growth, we suppressed TPL2 expression or activity either by shRNA-mediated knockdown or by TPL2 inhibitor treatment, respectively.